nodes	percent_of_prediction	percent_of_DWPC	metapath
Naltrexone—UGT1A1—Sorafenib—liver cancer	0.465	0.758	CbGbCtD
Naltrexone—ABCB1—Sorafenib—liver cancer	0.0923	0.15	CbGbCtD
Naltrexone—ABCB1—Doxorubicin—liver cancer	0.056	0.0913	CbGbCtD
Naltrexone—Cough—Sorafenib—liver cancer	0.00103	0.00385	CcSEcCtD
Naltrexone—Hypertension—Sorafenib—liver cancer	0.00102	0.00381	CcSEcCtD
Naltrexone—Cellulitis—Doxorubicin—liver cancer	0.00101	0.0038	CcSEcCtD
Naltrexone—Thinking abnormal—Doxorubicin—liver cancer	0.00101	0.00377	CcSEcCtD
Naltrexone—Arthralgia—Sorafenib—liver cancer	0.001	0.00376	CcSEcCtD
Naltrexone—Myalgia—Sorafenib—liver cancer	0.001	0.00376	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.000996	0.00373	CcSEcCtD
Naltrexone—Pulmonary embolism—Epirubicin—liver cancer	0.000996	0.00373	CcSEcCtD
Naltrexone—Injection site reaction—Epirubicin—liver cancer	0.00099	0.00371	CcSEcCtD
Naltrexone—Abnormal dreams—Epirubicin—liver cancer	0.000984	0.00369	CcSEcCtD
Naltrexone—Dry mouth—Sorafenib—liver cancer	0.000981	0.00368	CcSEcCtD
Naltrexone—Ulcer—Doxorubicin—liver cancer	0.000974	0.00365	CcSEcCtD
Naltrexone—Anaphylactic shock—Sorafenib—liver cancer	0.000961	0.0036	CcSEcCtD
Naltrexone—Colitis—Epirubicin—liver cancer	0.000956	0.00358	CcSEcCtD
Naltrexone—Infection—Sorafenib—liver cancer	0.000955	0.00358	CcSEcCtD
Naltrexone—Shock—Sorafenib—liver cancer	0.000946	0.00354	CcSEcCtD
Naltrexone—Nervous system disorder—Sorafenib—liver cancer	0.000943	0.00353	CcSEcCtD
Naltrexone—Skin disorder—Sorafenib—liver cancer	0.000934	0.0035	CcSEcCtD
Naltrexone—Pulmonary embolism—Doxorubicin—liver cancer	0.000921	0.00345	CcSEcCtD
Naltrexone—Anorexia—Sorafenib—liver cancer	0.000916	0.00343	CcSEcCtD
Naltrexone—Injection site reaction—Doxorubicin—liver cancer	0.000916	0.00343	CcSEcCtD
Naltrexone—Abnormal dreams—Doxorubicin—liver cancer	0.000911	0.00341	CcSEcCtD
Naltrexone—Colitis—Doxorubicin—liver cancer	0.000885	0.00332	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Sorafenib—liver cancer	0.000876	0.00328	CcSEcCtD
Naltrexone—Mental disability—Epirubicin—liver cancer	0.000864	0.00324	CcSEcCtD
Naltrexone—Dyspnoea—Sorafenib—liver cancer	0.000857	0.00321	CcSEcCtD
Naltrexone—Lymphadenopathy—Epirubicin—liver cancer	0.000847	0.00318	CcSEcCtD
Naltrexone—Phlebitis—Epirubicin—liver cancer	0.000839	0.00314	CcSEcCtD
Naltrexone—Decreased appetite—Sorafenib—liver cancer	0.000836	0.00313	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Sorafenib—liver cancer	0.00083	0.00311	CcSEcCtD
Naltrexone—Fatigue—Sorafenib—liver cancer	0.000829	0.00311	CcSEcCtD
Naltrexone—Pain—Sorafenib—liver cancer	0.000822	0.00308	CcSEcCtD
Naltrexone—Constipation—Sorafenib—liver cancer	0.000822	0.00308	CcSEcCtD
Naltrexone—Mental disability—Doxorubicin—liver cancer	0.0008	0.003	CcSEcCtD
Naltrexone—Cardiac failure congestive—Epirubicin—liver cancer	0.000797	0.00299	CcSEcCtD
Naltrexone—Gastrointestinal pain—Sorafenib—liver cancer	0.000786	0.00295	CcSEcCtD
Naltrexone—Lymphadenopathy—Doxorubicin—liver cancer	0.000784	0.00294	CcSEcCtD
Naltrexone—Phlebitis—Doxorubicin—liver cancer	0.000776	0.00291	CcSEcCtD
Naltrexone—Hot flush—Epirubicin—liver cancer	0.000773	0.0029	CcSEcCtD
Naltrexone—Increased appetite—Epirubicin—liver cancer	0.000769	0.00288	CcSEcCtD
Naltrexone—Menopausal symptoms—Epirubicin—liver cancer	0.000766	0.00287	CcSEcCtD
Naltrexone—Urticaria—Sorafenib—liver cancer	0.000764	0.00286	CcSEcCtD
Naltrexone—Abdominal pain—Sorafenib—liver cancer	0.00076	0.00285	CcSEcCtD
Naltrexone—Body temperature increased—Sorafenib—liver cancer	0.00076	0.00285	CcSEcCtD
Naltrexone—Purpura—Epirubicin—liver cancer	0.00075	0.00281	CcSEcCtD
Naltrexone—Lethargy—Epirubicin—liver cancer	0.000738	0.00276	CcSEcCtD
Naltrexone—Cardiac failure congestive—Doxorubicin—liver cancer	0.000738	0.00276	CcSEcCtD
Naltrexone—Gastrointestinal haemorrhage—Epirubicin—liver cancer	0.000723	0.00271	CcSEcCtD
Naltrexone—Pain in extremity—Epirubicin—liver cancer	0.000723	0.00271	CcSEcCtD
Naltrexone—Hot flush—Doxorubicin—liver cancer	0.000715	0.00268	CcSEcCtD
Naltrexone—Increased appetite—Doxorubicin—liver cancer	0.000712	0.00267	CcSEcCtD
Naltrexone—Migraine—Epirubicin—liver cancer	0.000712	0.00267	CcSEcCtD
Naltrexone—Menopausal symptoms—Doxorubicin—liver cancer	0.000709	0.00266	CcSEcCtD
Naltrexone—Hypersensitivity—Sorafenib—liver cancer	0.000708	0.00265	CcSEcCtD
Naltrexone—Face oedema—Epirubicin—liver cancer	0.000698	0.00262	CcSEcCtD
Naltrexone—Purpura—Doxorubicin—liver cancer	0.000694	0.0026	CcSEcCtD
Naltrexone—Asthenia—Sorafenib—liver cancer	0.00069	0.00258	CcSEcCtD
Naltrexone—Lethargy—Doxorubicin—liver cancer	0.000683	0.00256	CcSEcCtD
Naltrexone—Pruritus—Sorafenib—liver cancer	0.00068	0.00255	CcSEcCtD
Naltrexone—Dehydration—Epirubicin—liver cancer	0.000672	0.00252	CcSEcCtD
Naltrexone—Pain in extremity—Doxorubicin—liver cancer	0.000669	0.00251	CcSEcCtD
Naltrexone—Gastrointestinal haemorrhage—Doxorubicin—liver cancer	0.000669	0.00251	CcSEcCtD
Naltrexone—Abdominal pain upper—Epirubicin—liver cancer	0.00066	0.00247	CcSEcCtD
Naltrexone—Migraine—Doxorubicin—liver cancer	0.000658	0.00247	CcSEcCtD
Naltrexone—Diarrhoea—Sorafenib—liver cancer	0.000658	0.00247	CcSEcCtD
Naltrexone—Aspartate aminotransferase increased—Epirubicin—liver cancer	0.000651	0.00244	CcSEcCtD
Naltrexone—Nasopharyngitis—Epirubicin—liver cancer	0.000646	0.00242	CcSEcCtD
Naltrexone—Face oedema—Doxorubicin—liver cancer	0.000646	0.00242	CcSEcCtD
Naltrexone—Alanine aminotransferase increased—Epirubicin—liver cancer	0.000638	0.00239	CcSEcCtD
Naltrexone—Dizziness—Sorafenib—liver cancer	0.000636	0.00238	CcSEcCtD
Naltrexone—Influenza—Epirubicin—liver cancer	0.000625	0.00234	CcSEcCtD
Naltrexone—Dehydration—Doxorubicin—liver cancer	0.000622	0.00233	CcSEcCtD
Naltrexone—Vomiting—Sorafenib—liver cancer	0.000611	0.00229	CcSEcCtD
Naltrexone—Abdominal pain upper—Doxorubicin—liver cancer	0.000611	0.00229	CcSEcCtD
Naltrexone—Angina pectoris—Epirubicin—liver cancer	0.000609	0.00228	CcSEcCtD
Naltrexone—Rash—Sorafenib—liver cancer	0.000606	0.00227	CcSEcCtD
Naltrexone—Dermatitis—Sorafenib—liver cancer	0.000606	0.00227	CcSEcCtD
Naltrexone—Aspartate aminotransferase increased—Doxorubicin—liver cancer	0.000602	0.00226	CcSEcCtD
Naltrexone—Headache—Sorafenib—liver cancer	0.000602	0.00226	CcSEcCtD
Naltrexone—Bronchitis—Epirubicin—liver cancer	0.000601	0.00225	CcSEcCtD
Naltrexone—Nasopharyngitis—Doxorubicin—liver cancer	0.000598	0.00224	CcSEcCtD
Naltrexone—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.00059	0.00221	CcSEcCtD
Naltrexone—Upper respiratory tract infection—Epirubicin—liver cancer	0.000581	0.00218	CcSEcCtD
Naltrexone—Influenza—Doxorubicin—liver cancer	0.000578	0.00217	CcSEcCtD
Naltrexone—Nausea—Sorafenib—liver cancer	0.000571	0.00214	CcSEcCtD
Naltrexone—Weight increased—Epirubicin—liver cancer	0.000569	0.00213	CcSEcCtD
Naltrexone—Weight decreased—Epirubicin—liver cancer	0.000565	0.00212	CcSEcCtD
Naltrexone—Angina pectoris—Doxorubicin—liver cancer	0.000563	0.00211	CcSEcCtD
Naltrexone—Pneumonia—Epirubicin—liver cancer	0.00056	0.0021	CcSEcCtD
Naltrexone—Infestation NOS—Epirubicin—liver cancer	0.000557	0.00209	CcSEcCtD
Naltrexone—Infestation—Epirubicin—liver cancer	0.000557	0.00209	CcSEcCtD
Naltrexone—Bronchitis—Doxorubicin—liver cancer	0.000556	0.00208	CcSEcCtD
Naltrexone—Conjunctivitis—Epirubicin—liver cancer	0.000541	0.00203	CcSEcCtD
Naltrexone—Urinary tract infection—Epirubicin—liver cancer	0.000541	0.00203	CcSEcCtD
Naltrexone—Upper respiratory tract infection—Doxorubicin—liver cancer	0.000537	0.00201	CcSEcCtD
Naltrexone—Hepatobiliary disease—Epirubicin—liver cancer	0.000527	0.00197	CcSEcCtD
Naltrexone—Weight increased—Doxorubicin—liver cancer	0.000526	0.00197	CcSEcCtD
Naltrexone—Epistaxis—Epirubicin—liver cancer	0.000525	0.00197	CcSEcCtD
Naltrexone—Weight decreased—Doxorubicin—liver cancer	0.000523	0.00196	CcSEcCtD
Naltrexone—Sinusitis—Epirubicin—liver cancer	0.000523	0.00196	CcSEcCtD
Naltrexone—Pneumonia—Doxorubicin—liver cancer	0.000518	0.00194	CcSEcCtD
Naltrexone—Infestation NOS—Doxorubicin—liver cancer	0.000515	0.00193	CcSEcCtD
Naltrexone—Infestation—Doxorubicin—liver cancer	0.000515	0.00193	CcSEcCtD
Naltrexone—Conjunctivitis—Doxorubicin—liver cancer	0.000501	0.00188	CcSEcCtD
Naltrexone—Urinary tract infection—Doxorubicin—liver cancer	0.000501	0.00188	CcSEcCtD
Naltrexone—Hepatitis—Epirubicin—liver cancer	0.0005	0.00187	CcSEcCtD
Naltrexone—Pharyngitis—Epirubicin—liver cancer	0.000496	0.00186	CcSEcCtD
Naltrexone—Connective tissue disorder—Epirubicin—liver cancer	0.000491	0.00184	CcSEcCtD
Naltrexone—Hepatobiliary disease—Doxorubicin—liver cancer	0.000487	0.00183	CcSEcCtD
Naltrexone—Epistaxis—Doxorubicin—liver cancer	0.000486	0.00182	CcSEcCtD
Naltrexone—Sinusitis—Doxorubicin—liver cancer	0.000484	0.00181	CcSEcCtD
Naltrexone—Eye disorder—Epirubicin—liver cancer	0.000467	0.00175	CcSEcCtD
Naltrexone—Tinnitus—Epirubicin—liver cancer	0.000466	0.00175	CcSEcCtD
Naltrexone—Cardiac disorder—Epirubicin—liver cancer	0.000464	0.00174	CcSEcCtD
Naltrexone—Hepatitis—Doxorubicin—liver cancer	0.000463	0.00173	CcSEcCtD
Naltrexone—Pharyngitis—Doxorubicin—liver cancer	0.000459	0.00172	CcSEcCtD
Naltrexone—Connective tissue disorder—Doxorubicin—liver cancer	0.000455	0.0017	CcSEcCtD
Naltrexone—Naloxone—ESR1—liver cancer	0.000454	0.692	CrCbGaD
Naltrexone—Angiopathy—Epirubicin—liver cancer	0.000454	0.0017	CcSEcCtD
Naltrexone—Immune system disorder—Epirubicin—liver cancer	0.000452	0.00169	CcSEcCtD
Naltrexone—Mediastinal disorder—Epirubicin—liver cancer	0.000451	0.00169	CcSEcCtD
Naltrexone—Chills—Epirubicin—liver cancer	0.000449	0.00168	CcSEcCtD
Naltrexone—Alopecia—Epirubicin—liver cancer	0.000442	0.00166	CcSEcCtD
Naltrexone—Mental disorder—Epirubicin—liver cancer	0.000438	0.00164	CcSEcCtD
Naltrexone—Malnutrition—Epirubicin—liver cancer	0.000435	0.00163	CcSEcCtD
Naltrexone—Eye disorder—Doxorubicin—liver cancer	0.000432	0.00162	CcSEcCtD
Naltrexone—Tinnitus—Doxorubicin—liver cancer	0.000431	0.00162	CcSEcCtD
Naltrexone—Cardiac disorder—Doxorubicin—liver cancer	0.000429	0.00161	CcSEcCtD
Naltrexone—Flatulence—Epirubicin—liver cancer	0.000429	0.00161	CcSEcCtD
Naltrexone—Tension—Epirubicin—liver cancer	0.000427	0.0016	CcSEcCtD
Naltrexone—Dysgeusia—Epirubicin—liver cancer	0.000426	0.0016	CcSEcCtD
Naltrexone—Nervousness—Epirubicin—liver cancer	0.000423	0.00158	CcSEcCtD
Naltrexone—Back pain—Epirubicin—liver cancer	0.000421	0.00158	CcSEcCtD
Naltrexone—Angiopathy—Doxorubicin—liver cancer	0.00042	0.00157	CcSEcCtD
Naltrexone—Muscle spasms—Epirubicin—liver cancer	0.000419	0.00157	CcSEcCtD
Naltrexone—Immune system disorder—Doxorubicin—liver cancer	0.000418	0.00157	CcSEcCtD
Naltrexone—Mediastinal disorder—Doxorubicin—liver cancer	0.000417	0.00156	CcSEcCtD
Naltrexone—Chills—Doxorubicin—liver cancer	0.000415	0.00156	CcSEcCtD
Naltrexone—Vision blurred—Epirubicin—liver cancer	0.00041	0.00154	CcSEcCtD
Naltrexone—Alopecia—Doxorubicin—liver cancer	0.000409	0.00153	CcSEcCtD
Naltrexone—Mental disorder—Doxorubicin—liver cancer	0.000405	0.00152	CcSEcCtD
Naltrexone—Ill-defined disorder—Epirubicin—liver cancer	0.000404	0.00151	CcSEcCtD
Naltrexone—Malnutrition—Doxorubicin—liver cancer	0.000403	0.00151	CcSEcCtD
Naltrexone—Agitation—Epirubicin—liver cancer	0.0004	0.0015	CcSEcCtD
Naltrexone—Flatulence—Doxorubicin—liver cancer	0.000397	0.00149	CcSEcCtD
Naltrexone—Tension—Doxorubicin—liver cancer	0.000395	0.00148	CcSEcCtD
Naltrexone—Dysgeusia—Doxorubicin—liver cancer	0.000394	0.00148	CcSEcCtD
Naltrexone—Malaise—Epirubicin—liver cancer	0.000393	0.00147	CcSEcCtD
Naltrexone—Nervousness—Doxorubicin—liver cancer	0.000391	0.00147	CcSEcCtD
Naltrexone—Syncope—Epirubicin—liver cancer	0.00039	0.00146	CcSEcCtD
Naltrexone—Back pain—Doxorubicin—liver cancer	0.00039	0.00146	CcSEcCtD
Naltrexone—Muscle spasms—Doxorubicin—liver cancer	0.000387	0.00145	CcSEcCtD
Naltrexone—Palpitations—Epirubicin—liver cancer	0.000385	0.00144	CcSEcCtD
Naltrexone—Loss of consciousness—Epirubicin—liver cancer	0.000383	0.00143	CcSEcCtD
Naltrexone—Cough—Epirubicin—liver cancer	0.00038	0.00142	CcSEcCtD
Naltrexone—Vision blurred—Doxorubicin—liver cancer	0.00038	0.00142	CcSEcCtD
Naltrexone—Convulsion—Epirubicin—liver cancer	0.000377	0.00141	CcSEcCtD
Naltrexone—Hypertension—Epirubicin—liver cancer	0.000376	0.00141	CcSEcCtD
Naltrexone—Ill-defined disorder—Doxorubicin—liver cancer	0.000374	0.0014	CcSEcCtD
Naltrexone—Chest pain—Epirubicin—liver cancer	0.000371	0.00139	CcSEcCtD
Naltrexone—Myalgia—Epirubicin—liver cancer	0.000371	0.00139	CcSEcCtD
Naltrexone—Arthralgia—Epirubicin—liver cancer	0.000371	0.00139	CcSEcCtD
Naltrexone—Agitation—Doxorubicin—liver cancer	0.00037	0.00139	CcSEcCtD
Naltrexone—Anxiety—Epirubicin—liver cancer	0.000369	0.00138	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000368	0.00138	CcSEcCtD
Naltrexone—Discomfort—Epirubicin—liver cancer	0.000366	0.00137	CcSEcCtD
Naltrexone—Malaise—Doxorubicin—liver cancer	0.000363	0.00136	CcSEcCtD
Naltrexone—Dry mouth—Epirubicin—liver cancer	0.000362	0.00136	CcSEcCtD
Naltrexone—Syncope—Doxorubicin—liver cancer	0.000361	0.00135	CcSEcCtD
Naltrexone—Confusional state—Epirubicin—liver cancer	0.000358	0.00134	CcSEcCtD
Naltrexone—Palpitations—Doxorubicin—liver cancer	0.000356	0.00133	CcSEcCtD
Naltrexone—Anaphylactic shock—Epirubicin—liver cancer	0.000355	0.00133	CcSEcCtD
Naltrexone—Oedema—Epirubicin—liver cancer	0.000355	0.00133	CcSEcCtD
Naltrexone—Loss of consciousness—Doxorubicin—liver cancer	0.000354	0.00133	CcSEcCtD
Naltrexone—Infection—Epirubicin—liver cancer	0.000353	0.00132	CcSEcCtD
Naltrexone—Cough—Doxorubicin—liver cancer	0.000351	0.00132	CcSEcCtD
Naltrexone—Shock—Epirubicin—liver cancer	0.00035	0.00131	CcSEcCtD
Naltrexone—Convulsion—Doxorubicin—liver cancer	0.000349	0.00131	CcSEcCtD
Naltrexone—Nervous system disorder—Epirubicin—liver cancer	0.000348	0.00131	CcSEcCtD
Naltrexone—Hypertension—Doxorubicin—liver cancer	0.000348	0.0013	CcSEcCtD
Naltrexone—Tachycardia—Epirubicin—liver cancer	0.000347	0.0013	CcSEcCtD
Naltrexone—Skin disorder—Epirubicin—liver cancer	0.000345	0.00129	CcSEcCtD
Naltrexone—Hyperhidrosis—Epirubicin—liver cancer	0.000343	0.00129	CcSEcCtD
Naltrexone—Arthralgia—Doxorubicin—liver cancer	0.000343	0.00129	CcSEcCtD
Naltrexone—Myalgia—Doxorubicin—liver cancer	0.000343	0.00129	CcSEcCtD
Naltrexone—Chest pain—Doxorubicin—liver cancer	0.000343	0.00129	CcSEcCtD
Naltrexone—Anxiety—Doxorubicin—liver cancer	0.000342	0.00128	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000341	0.00128	CcSEcCtD
Naltrexone—Discomfort—Doxorubicin—liver cancer	0.000339	0.00127	CcSEcCtD
Naltrexone—Anorexia—Epirubicin—liver cancer	0.000339	0.00127	CcSEcCtD
Naltrexone—Dry mouth—Doxorubicin—liver cancer	0.000335	0.00126	CcSEcCtD
Naltrexone—Confusional state—Doxorubicin—liver cancer	0.000331	0.00124	CcSEcCtD
Naltrexone—Oedema—Doxorubicin—liver cancer	0.000329	0.00123	CcSEcCtD
Naltrexone—Anaphylactic shock—Doxorubicin—liver cancer	0.000329	0.00123	CcSEcCtD
Naltrexone—Infection—Doxorubicin—liver cancer	0.000327	0.00122	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000324	0.00121	CcSEcCtD
Naltrexone—Shock—Doxorubicin—liver cancer	0.000323	0.00121	CcSEcCtD
Naltrexone—Nervous system disorder—Doxorubicin—liver cancer	0.000322	0.00121	CcSEcCtD
Naltrexone—Insomnia—Epirubicin—liver cancer	0.000321	0.0012	CcSEcCtD
Naltrexone—Tachycardia—Doxorubicin—liver cancer	0.000321	0.0012	CcSEcCtD
Naltrexone—Skin disorder—Doxorubicin—liver cancer	0.000319	0.0012	CcSEcCtD
Naltrexone—Paraesthesia—Epirubicin—liver cancer	0.000319	0.0012	CcSEcCtD
Naltrexone—Hyperhidrosis—Doxorubicin—liver cancer	0.000318	0.00119	CcSEcCtD
Naltrexone—Dyspnoea—Epirubicin—liver cancer	0.000317	0.00119	CcSEcCtD
Naltrexone—Somnolence—Epirubicin—liver cancer	0.000316	0.00118	CcSEcCtD
Naltrexone—Anorexia—Doxorubicin—liver cancer	0.000313	0.00117	CcSEcCtD
Naltrexone—Decreased appetite—Epirubicin—liver cancer	0.000309	0.00116	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Epirubicin—liver cancer	0.000307	0.00115	CcSEcCtD
Naltrexone—Fatigue—Epirubicin—liver cancer	0.000306	0.00115	CcSEcCtD
Naltrexone—Pain—Epirubicin—liver cancer	0.000304	0.00114	CcSEcCtD
Naltrexone—Constipation—Epirubicin—liver cancer	0.000304	0.00114	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.0003	0.00112	CcSEcCtD
Naltrexone—Insomnia—Doxorubicin—liver cancer	0.000297	0.00111	CcSEcCtD
Naltrexone—Paraesthesia—Doxorubicin—liver cancer	0.000295	0.00111	CcSEcCtD
Naltrexone—Dyspnoea—Doxorubicin—liver cancer	0.000293	0.0011	CcSEcCtD
Naltrexone—Feeling abnormal—Epirubicin—liver cancer	0.000293	0.0011	CcSEcCtD
Naltrexone—Somnolence—Doxorubicin—liver cancer	0.000292	0.0011	CcSEcCtD
Naltrexone—Gastrointestinal pain—Epirubicin—liver cancer	0.000291	0.00109	CcSEcCtD
Naltrexone—Decreased appetite—Doxorubicin—liver cancer	0.000286	0.00107	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000284	0.00106	CcSEcCtD
Naltrexone—Fatigue—Doxorubicin—liver cancer	0.000283	0.00106	CcSEcCtD
Naltrexone—Urticaria—Epirubicin—liver cancer	0.000282	0.00106	CcSEcCtD
Naltrexone—Constipation—Doxorubicin—liver cancer	0.000281	0.00105	CcSEcCtD
Naltrexone—Pain—Doxorubicin—liver cancer	0.000281	0.00105	CcSEcCtD
Naltrexone—Abdominal pain—Epirubicin—liver cancer	0.000281	0.00105	CcSEcCtD
Naltrexone—Body temperature increased—Epirubicin—liver cancer	0.000281	0.00105	CcSEcCtD
Naltrexone—Feeling abnormal—Doxorubicin—liver cancer	0.000271	0.00102	CcSEcCtD
Naltrexone—Gastrointestinal pain—Doxorubicin—liver cancer	0.000269	0.00101	CcSEcCtD
Naltrexone—Hypersensitivity—Epirubicin—liver cancer	0.000262	0.000981	CcSEcCtD
Naltrexone—Urticaria—Doxorubicin—liver cancer	0.000261	0.000979	CcSEcCtD
Naltrexone—Abdominal pain—Doxorubicin—liver cancer	0.00026	0.000974	CcSEcCtD
Naltrexone—Body temperature increased—Doxorubicin—liver cancer	0.00026	0.000974	CcSEcCtD
Naltrexone—Asthenia—Epirubicin—liver cancer	0.000255	0.000955	CcSEcCtD
Naltrexone—Pruritus—Epirubicin—liver cancer	0.000251	0.000942	CcSEcCtD
Naltrexone—Diarrhoea—Epirubicin—liver cancer	0.000243	0.000911	CcSEcCtD
Naltrexone—Hypersensitivity—Doxorubicin—liver cancer	0.000242	0.000908	CcSEcCtD
Naltrexone—Asthenia—Doxorubicin—liver cancer	0.000236	0.000884	CcSEcCtD
Naltrexone—Dizziness—Epirubicin—liver cancer	0.000235	0.00088	CcSEcCtD
Naltrexone—Pruritus—Doxorubicin—liver cancer	0.000233	0.000872	CcSEcCtD
Naltrexone—Vomiting—Epirubicin—liver cancer	0.000226	0.000847	CcSEcCtD
Naltrexone—Diarrhoea—Doxorubicin—liver cancer	0.000225	0.000843	CcSEcCtD
Naltrexone—Rash—Epirubicin—liver cancer	0.000224	0.00084	CcSEcCtD
Naltrexone—Dermatitis—Epirubicin—liver cancer	0.000224	0.000839	CcSEcCtD
Naltrexone—Headache—Epirubicin—liver cancer	0.000223	0.000834	CcSEcCtD
Naltrexone—Dizziness—Doxorubicin—liver cancer	0.000217	0.000815	CcSEcCtD
Naltrexone—Nausea—Epirubicin—liver cancer	0.000211	0.000791	CcSEcCtD
Naltrexone—Vomiting—Doxorubicin—liver cancer	0.000209	0.000783	CcSEcCtD
Naltrexone—Rash—Doxorubicin—liver cancer	0.000207	0.000777	CcSEcCtD
Naltrexone—Dermatitis—Doxorubicin—liver cancer	0.000207	0.000776	CcSEcCtD
Naltrexone—Headache—Doxorubicin—liver cancer	0.000206	0.000772	CcSEcCtD
Naltrexone—Naloxone—ALB—liver cancer	0.000202	0.308	CrCbGaD
Naltrexone—Nausea—Doxorubicin—liver cancer	0.000195	0.000732	CcSEcCtD
Naltrexone—OPRM1—Signaling Pathways—TRIO—liver cancer	7.94e-05	0.000668	CbGpPWpGaD
Naltrexone—ABCB1—HIF-1-alpha transcription factor network—AKT1—liver cancer	7.84e-05	0.00066	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CSF2—liver cancer	7.76e-05	0.000654	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—HPGDS—liver cancer	7.76e-05	0.000654	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—F2—liver cancer	7.65e-05	0.000644	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PSMA4—liver cancer	7.63e-05	0.000643	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PSMD10—liver cancer	7.63e-05	0.000643	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CCR4—liver cancer	7.61e-05	0.000641	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—PRKCE—liver cancer	7.42e-05	0.000625	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—PIK3CG—liver cancer	7.32e-05	0.000617	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—CSF2—liver cancer	7.23e-05	0.000609	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ADAM17—liver cancer	7.12e-05	0.000599	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—F2—liver cancer	6.95e-05	0.000585	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PSMA4—liver cancer	6.92e-05	0.000583	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PSMD10—liver cancer	6.92e-05	0.000583	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—liver cancer	6.89e-05	0.00058	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—GOT2—liver cancer	6.73e-05	0.000567	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—F2—liver cancer	6.71e-05	0.000565	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PSMA4—liver cancer	6.69e-05	0.000564	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PSMD10—liver cancer	6.69e-05	0.000564	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—PIK3CG—liver cancer	6.65e-05	0.00056	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CSF2—liver cancer	6.56e-05	0.000553	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—PIK3CD—liver cancer	6.44e-05	0.000542	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—PIK3CG—liver cancer	6.42e-05	0.000541	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CYP2E1—liver cancer	6.33e-05	0.000533	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—liver cancer	6.32e-05	0.000532	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—liver cancer	6.19e-05	0.000521	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—F2—liver cancer	6.09e-05	0.000513	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—liver cancer	6.02e-05	0.000507	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ADAM17—liver cancer	6.02e-05	0.000507	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—liver cancer	6.01e-05	0.000506	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—liver cancer	5.97e-05	0.000502	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CYCS—liver cancer	5.92e-05	0.000499	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PRKCE—liver cancer	5.91e-05	0.000498	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—PIK3CD—liver cancer	5.85e-05	0.000492	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—PIK3CG—liver cancer	5.83e-05	0.000491	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—liver cancer	5.83e-05	0.000491	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—GOT1—liver cancer	5.81e-05	0.000489	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—GGT1—liver cancer	5.81e-05	0.000489	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—CYCS—liver cancer	5.8e-05	0.000488	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—liver cancer	5.69e-05	0.000479	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—F2—liver cancer	5.67e-05	0.000478	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PSMD10—liver cancer	5.66e-05	0.000476	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PSMA4—liver cancer	5.66e-05	0.000476	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—PIK3CD—liver cancer	5.64e-05	0.000475	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—PIK3CB—liver cancer	5.61e-05	0.000473	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IGF2—liver cancer	5.6e-05	0.000472	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CPT1B—liver cancer	5.53e-05	0.000465	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GLUL—liver cancer	5.53e-05	0.000465	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—PIK3CG—liver cancer	5.43e-05	0.000457	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—NR1H4—liver cancer	5.33e-05	0.000449	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—liver cancer	5.25e-05	0.000442	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GSTA3—liver cancer	5.24e-05	0.000441	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CSF2—liver cancer	5.23e-05	0.000441	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—RAF1—liver cancer	5.22e-05	0.000439	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—GSTP1—liver cancer	5.22e-05	0.000439	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PRKCE—liver cancer	5.18e-05	0.000437	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—H2AFX—liver cancer	5.16e-05	0.000434	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—IL2—liver cancer	5.15e-05	0.000434	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—F2—liver cancer	5.15e-05	0.000434	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—HMOX1—liver cancer	5.15e-05	0.000433	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—PIK3CD—liver cancer	5.13e-05	0.000432	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—PIK3CB—liver cancer	5.1e-05	0.000429	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—HMOX1—liver cancer	5.04e-05	0.000424	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—PIK3CG—liver cancer	4.93e-05	0.000415	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—PIK3CB—liver cancer	4.92e-05	0.000414	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IGF2—liver cancer	4.91e-05	0.000414	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—liver cancer	4.83e-05	0.000407	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—liver cancer	4.82e-05	0.000406	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—GSTM1—liver cancer	4.79e-05	0.000404	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GSTA4—liver cancer	4.79e-05	0.000403	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—PIK3CD—liver cancer	4.77e-05	0.000402	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—IL2—liver cancer	4.68e-05	0.000394	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GSTA2—liver cancer	4.67e-05	0.000393	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TERT—liver cancer	4.66e-05	0.000393	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CSF2—liver cancer	4.59e-05	0.000386	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—RAF1—liver cancer	4.58e-05	0.000385	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CYP1A1—liver cancer	4.55e-05	0.000383	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—H2AFX—liver cancer	4.52e-05	0.000381	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—IL2—liver cancer	4.52e-05	0.000381	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GSTA1—liver cancer	4.5e-05	0.000379	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—liver cancer	4.5e-05	0.000379	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—PIK3CB—liver cancer	4.47e-05	0.000376	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—liver cancer	4.47e-05	0.000376	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—NAT2—liver cancer	4.45e-05	0.000375	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PRKCE—liver cancer	4.38e-05	0.000369	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—PIK3CD—liver cancer	4.33e-05	0.000365	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ALDOB—liver cancer	4.27e-05	0.00036	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—KDR—liver cancer	4.26e-05	0.000359	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—MTHFR—liver cancer	4.24e-05	0.000357	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MAPK14—liver cancer	4.24e-05	0.000357	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—PIK3CB—liver cancer	4.16e-05	0.00035	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PPARA—liver cancer	4.16e-05	0.00035	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—ESR1—liver cancer	4.16e-05	0.00035	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IGF2—liver cancer	4.15e-05	0.00035	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—F2—liver cancer	4.1e-05	0.000346	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—IL2—liver cancer	4.1e-05	0.000346	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—liver cancer	4.1e-05	0.000345	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TERT—liver cancer	4.09e-05	0.000344	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CRABP1—liver cancer	4.07e-05	0.000343	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—PPARA—liver cancer	4.07e-05	0.000343	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—liver cancer	3.97e-05	0.000334	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—APC—liver cancer	3.93e-05	0.000331	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PIK3CG—liver cancer	3.93e-05	0.000331	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CSF2—liver cancer	3.88e-05	0.000326	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—RAF1—liver cancer	3.87e-05	0.000326	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—H2AFX—liver cancer	3.82e-05	0.000322	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—IL2—liver cancer	3.82e-05	0.000322	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—PIK3CB—liver cancer	3.78e-05	0.000318	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—KDR—liver cancer	3.74e-05	0.000315	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MAPK14—liver cancer	3.71e-05	0.000313	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—BRAF—liver cancer	3.69e-05	0.000311	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ESR1—liver cancer	3.64e-05	0.000307	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—F2—liver cancer	3.6e-05	0.000303	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PIK3CG—liver cancer	3.56e-05	0.0003	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—HPGDS—liver cancer	3.56e-05	0.0003	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—IL2—liver cancer	3.47e-05	0.000292	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TERT—liver cancer	3.46e-05	0.000291	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PIK3CD—liver cancer	3.45e-05	0.000291	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—APC—liver cancer	3.44e-05	0.00029	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PIK3CG—liver cancer	3.44e-05	0.00029	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PPARG—liver cancer	3.44e-05	0.000289	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—PIK3CA—liver cancer	3.42e-05	0.000288	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—SERPINE1—liver cancer	3.42e-05	0.000288	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—KRAS—liver cancer	3.38e-05	0.000285	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—liver cancer	3.35e-05	0.000282	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—BRAF—liver cancer	3.24e-05	0.000273	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PSMD10—liver cancer	3.17e-05	0.000267	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PSMA4—liver cancer	3.17e-05	0.000267	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—KDR—liver cancer	3.16e-05	0.000266	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MAPK14—liver cancer	3.14e-05	0.000264	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PIK3CD—liver cancer	3.13e-05	0.000264	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—PIK3CA—liver cancer	3.11e-05	0.000262	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ALB—liver cancer	3.09e-05	0.00026	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GOT2—liver cancer	3.09e-05	0.00026	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—RAF1—liver cancer	3.08e-05	0.00026	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ESR1—liver cancer	3.08e-05	0.000259	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—F2—liver cancer	3.04e-05	0.000256	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PIK3CD—liver cancer	3.03e-05	0.000255	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—ALB—liver cancer	3.03e-05	0.000255	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MTOR—liver cancer	3.01e-05	0.000253	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PIK3CB—liver cancer	3.01e-05	0.000253	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—PIK3CA—liver cancer	3e-05	0.000253	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—SERPINE1—liver cancer	3e-05	0.000252	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—KRAS—liver cancer	2.96e-05	0.00025	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PIK3CG—liver cancer	2.91e-05	0.000245	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—APC—liver cancer	2.91e-05	0.000245	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP2E1—liver cancer	2.9e-05	0.000244	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—HRAS—liver cancer	2.87e-05	0.000242	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CDKN1B—liver cancer	2.82e-05	0.000238	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—AKT1—liver cancer	2.79e-05	0.000235	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CASP3—liver cancer	2.77e-05	0.000233	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IL2—liver cancer	2.76e-05	0.000233	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—IL6—liver cancer	2.75e-05	0.000232	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—RAF1—liver cancer	2.74e-05	0.00023	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—BRAF—liver cancer	2.74e-05	0.00023	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PIK3CB—liver cancer	2.73e-05	0.00023	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—PIK3CA—liver cancer	2.72e-05	0.000229	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYCS—liver cancer	2.72e-05	0.000229	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—RAF1—liver cancer	2.7e-05	0.000228	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CCND1—liver cancer	2.69e-05	0.000227	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—JUN—liver cancer	2.69e-05	0.000226	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CTNNB1—liver cancer	2.67e-05	0.000225	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GOT1—liver cancer	2.66e-05	0.000224	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GGT1—liver cancer	2.66e-05	0.000224	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PIK3CB—liver cancer	2.64e-05	0.000222	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MTOR—liver cancer	2.64e-05	0.000222	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MMP9—liver cancer	2.62e-05	0.00022	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CDKN1A—liver cancer	2.61e-05	0.00022	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PIK3CD—liver cancer	2.56e-05	0.000216	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MAPK8—liver cancer	2.54e-05	0.000214	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—AKT1—liver cancer	2.54e-05	0.000214	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—PIK3CA—liver cancer	2.53e-05	0.000213	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—SERPINE1—liver cancer	2.53e-05	0.000213	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—HRAS—liver cancer	2.52e-05	0.000212	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—KRAS—liver cancer	2.51e-05	0.000211	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CDKN1B—liver cancer	2.48e-05	0.000209	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—AKT1—liver cancer	2.45e-05	0.000206	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CASP3—liver cancer	2.43e-05	0.000204	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IL2—liver cancer	2.42e-05	0.000204	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—IL6—liver cancer	2.41e-05	0.000203	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GSTP1—liver cancer	2.39e-05	0.000202	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CCND1—liver cancer	2.36e-05	0.000199	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—HMOX1—liver cancer	2.36e-05	0.000199	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—JUN—liver cancer	2.36e-05	0.000199	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—VEGFA—liver cancer	2.35e-05	0.000198	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CTNNB1—liver cancer	2.34e-05	0.000197	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—STAT3—liver cancer	2.33e-05	0.000196	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—PIK3CA—liver cancer	2.3e-05	0.000194	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MMP9—liver cancer	2.29e-05	0.000193	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CDKN1A—liver cancer	2.29e-05	0.000193	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—RAF1—liver cancer	2.28e-05	0.000192	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MAPK8—liver cancer	2.23e-05	0.000188	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PIK3CB—liver cancer	2.23e-05	0.000188	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MTOR—liver cancer	2.23e-05	0.000188	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—AKT1—liver cancer	2.23e-05	0.000187	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GSTM1—liver cancer	2.2e-05	0.000185	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MYC—liver cancer	2.16e-05	0.000182	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TGFB1—liver cancer	2.16e-05	0.000182	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—HRAS—liver cancer	2.13e-05	0.000179	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CDKN1B—liver cancer	2.09e-05	0.000176	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP1A1—liver cancer	2.09e-05	0.000176	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—AKT1—liver cancer	2.07e-05	0.000174	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—VEGFA—liver cancer	2.06e-05	0.000173	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CASP3—liver cancer	2.05e-05	0.000173	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IL2—liver cancer	2.05e-05	0.000173	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—STAT3—liver cancer	2.04e-05	0.000172	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—IL6—liver cancer	2.04e-05	0.000172	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—KRAS—liver cancer	2e-05	0.000168	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CCND1—liver cancer	2e-05	0.000168	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—JUN—liver cancer	1.99e-05	0.000168	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CTNNB1—liver cancer	1.98e-05	0.000167	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—MTHFR—liver cancer	1.94e-05	0.000164	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MMP9—liver cancer	1.94e-05	0.000163	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CDKN1A—liver cancer	1.93e-05	0.000163	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PPARA—liver cancer	1.91e-05	0.000161	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MYC—liver cancer	1.9e-05	0.00016	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TGFB1—liver cancer	1.89e-05	0.000159	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MAPK8—liver cancer	1.89e-05	0.000159	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—AKT1—liver cancer	1.88e-05	0.000158	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PIK3CA—liver cancer	1.83e-05	0.000155	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TP53—liver cancer	1.78e-05	0.000149	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—KRAS—liver cancer	1.75e-05	0.000147	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—VEGFA—liver cancer	1.74e-05	0.000147	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—STAT3—liver cancer	1.72e-05	0.000145	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—HRAS—liver cancer	1.7e-05	0.000143	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PIK3CA—liver cancer	1.66e-05	0.00014	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PIK3CG—liver cancer	1.63e-05	0.000138	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IL6—liver cancer	1.62e-05	0.000137	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PIK3CA—liver cancer	1.61e-05	0.000135	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MYC—liver cancer	1.6e-05	0.000135	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TGFB1—liver cancer	1.6e-05	0.000135	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PPARG—liver cancer	1.58e-05	0.000133	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TP53—liver cancer	1.56e-05	0.000131	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—AKT1—liver cancer	1.5e-05	0.000126	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—HRAS—liver cancer	1.49e-05	0.000125	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—KRAS—liver cancer	1.48e-05	0.000125	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PIK3CD—liver cancer	1.44e-05	0.000121	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IL6—liver cancer	1.42e-05	0.00012	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ALB—liver cancer	1.42e-05	0.000119	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PIK3CA—liver cancer	1.36e-05	0.000115	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—AKT1—liver cancer	1.36e-05	0.000114	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TP53—liver cancer	1.32e-05	0.000111	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—AKT1—liver cancer	1.31e-05	0.000111	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HRAS—liver cancer	1.26e-05	0.000106	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PIK3CB—liver cancer	1.25e-05	0.000105	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IL6—liver cancer	1.2e-05	0.000101	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—AKT1—liver cancer	1.11e-05	9.35e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PIK3CA—liver cancer	7.63e-06	6.42e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—AKT1—liver cancer	6.23e-06	5.25e-05	CbGpPWpGaD
